Trials / Recruiting
RecruitingNCT06914245
Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients_contributing Factors (Treatable)
Towards Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients Through Precision Medicine
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- KU Leuven · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection combined with chemoradiotherapy. However, this treatment negatively affects various aspects of bowel function and patients' quality of life. These bowel symptoms often remain prevalent, even 12 months after RC treatment. The aim of this study is to identify the factors contributing to persistent bowel symptoms and their long-term impact on quality of life following treatment for rectal cancer, assessed 12 months after surgery or stoma closure in surgically treated patients, and 12 months after completion of neoadjuvant therapy in patients managed with active surveillance/watch-and-wait. These insights are crucial for developing an effective care approach, as they help determine when specific evaluations should be conducted and which treatments should be applied at different stages.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Electronic bowel diary | This bowel diary will be available on the smartphone in the form of an application. |
| DIAGNOSTIC_TEST | Faecal Incontinence Quality of Life questionnaire (FIQL) | This questionnaire will be available online. |
| DIAGNOSTIC_TEST | EuroQoL 5 dimensions, 5 levels (EQ-5D-5L) | This questionnaire will be available online. |
Timeline
- Start date
- 2025-04-28
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-04-06
- Last updated
- 2026-01-23
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06914245. Inclusion in this directory is not an endorsement.